Lexeo Therapeutics (LXEO) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

LXEO Lexeo Therapeutics

Watchlist

7.830
+0.500+6.82%

Close Nov 27 16:00 ET

7.940
+0.110+1.40%

Post 16:19 ET

258.91MMarket Cap-2989P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Paula H. Cholmondeley Bought 96% More Shares In Lexeo Therapeutics
Yahoo Finance05:18 ET
Baird Maintains Lexeo Therapeutics(LXEO.US) With Buy Rating, Maintains Target Price $28
Moomoo NewsNov 21 02:31 ET · Ratings
Lexeo Therapeutics' Promising Gene Therapy Progress and Strong Financial Position Present Attractive Investment Opportunity
TipRanksNov 21 01:36 ET
Here's Why We're Watching Lexeo Therapeutics' (NASDAQ:LXEO) Cash Burn Situation
Yahoo FinanceNov 20 07:09 ET
Lexeo Therapeutics Advances Cardiac Portfolio Amid Financial Report
TipRanksNov 14 23:35 ET
RBC Capital Maintains Lexeo Therapeutics(LXEO.US) With Buy Rating, Maintains Target Price $24
Moomoo NewsNov 14 21:32 ET · Ratings

Comments

Jaguar8

Nov 13 08:36

NEWS ER

$Lexeo Therapeutics (LXEO.US)$
Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results
Reached alignment with FDA on key elements of registrational development plan for LX2006, including accelerated approval pathway with left-ventricular mass index (LVMI) and frataxin protein expression as co-primary registrational endpoints
Received RMAT designation for LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy, potentially enabling...

Jaguar8

Apr 22 06:31

$Lexeo Therapeutics (LXEO.US)$
NEWS
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

Moomoo AI

Dec 11, 2023 06:44

Lexeo's CEO acknowledged significant progress made in 2023, credited to the successful IPO. He anticipates more clinical data from cardiovascular and Alzheimer's disease programs in 2024.